206 related articles for article (PubMed ID: 36081565)
1. Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status.
Roering P; Siddiqui A; Heuser VD; Potdar S; Mikkonen P; Oikkonen J; Li Y; Pikkusaari S; Wennerberg K; Hynninen J; Grenman S; Huhtinen K; Auranen A; Carpén O; Kaipio K
Front Oncol; 2022; 12():954430. PubMed ID: 36081565
[TBL] [Abstract][Full Text] [Related]
2. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
3. Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma.
Madariaga A; Mitchell SA; Pittman T; Wang L; Bowering V; Kavak N; Quintos J; Chang K; Ramsahai J; Karakasis K; Welch SA; Dhani NC; Lheureux S; Oza AM
Gynecol Oncol; 2022 Nov; 167(2):226-233. PubMed ID: 36055813
[TBL] [Abstract][Full Text] [Related]
4. Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets.
Voutsadakis IA
Cancer Manag Res; 2020; 12():10423-10437. PubMed ID: 33116896
[TBL] [Abstract][Full Text] [Related]
5. Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells.
Gomez MK; Illuzzi G; Colomer C; Churchman M; Hollis RL; O'Connor MJ; Gourley C; Leo E; Melton DW
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526907
[TBL] [Abstract][Full Text] [Related]
6. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
7. Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells.
Jia Y; Wang M; Sang X; Liu P; Gao J; Jiang K; Cheng H
Front Oncol; 2021; 11():812264. PubMed ID: 35155204
[TBL] [Abstract][Full Text] [Related]
8. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
9. Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients.
Li Y; Zhang X; Gao Y; Shang C; Yu B; Wang T; Su J; Huang C; Wu Y; Guo H; Ha C
Front Oncol; 2020; 10():625866. PubMed ID: 33747898
[TBL] [Abstract][Full Text] [Related]
10. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
[TBL] [Abstract][Full Text] [Related]
11. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
Wallbillich JJ; Morris RT; Ali-Fehmi R
Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
[TBL] [Abstract][Full Text] [Related]
12. Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.
Chen J; Jia X; Li Z; Song W; Jin C; Zhou M; Xie H; Zheng S; Song P
Biochem Pharmacol; 2021 Jun; 188():114494. PubMed ID: 33684390
[TBL] [Abstract][Full Text] [Related]
13. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
14. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
15. Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Bell HL; Blair HJ; Singh M; Moorman AV; Heidenreich O; van Delft FW; Lunec J; Irving JAE
Cancer Cell Int; 2023 Sep; 23(1):202. PubMed ID: 37715172
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
Lewis CW; Bukhari AB; Xiao EJ; Choi WS; Smith JD; Homola E; Mackey JR; Campbell SD; Gamper AM; Chan GK
Cancer Res; 2019 Dec; 79(23):5971-5985. PubMed ID: 31594837
[TBL] [Abstract][Full Text] [Related]
17. Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.
Wiedemeyer WR; Beach JA; Karlan BY
Front Oncol; 2014; 4():34. PubMed ID: 24624361
[TBL] [Abstract][Full Text] [Related]
18. Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases
Brill E; Yokoyama T; Nair J; Yu M; Ahn YR; Lee JM
Oncotarget; 2017 Dec; 8(67):111026-111040. PubMed ID: 29340034
[TBL] [Abstract][Full Text] [Related]
19. Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas.
Milanesio MC; Giordano S; Valabrega G
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455819
[TBL] [Abstract][Full Text] [Related]
20. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
Yan S; Xuan J; Brajanovski N; Tancock MRC; Madhamshettiwar PB; Simpson KJ; Ellis S; Kang J; Cullinane C; Sheppard KE; Hannan KM; Hannan RD; Sanij E; Pearson RB; Chan KT
Br J Cancer; 2021 Feb; 124(3):616-627. PubMed ID: 33173151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
